Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. (Q45933610)
Jump to navigation
Jump to search
scientific article published on 9 July 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. |
scientific article published on 9 July 2009 |
Statements
1 reference
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. (English)
1 reference
1 reference
Gianantonio Rosti
1 reference
Fausto Castagnetti
1 reference
Giovanni Martinelli
1 reference
Gabriele Gugliotta
1 reference
Michele Baccarani
1 reference
Ilaria Iacobucci
1 reference
Daniela Cilloni
1 reference
Stefania Paolini
1 reference
Angela Poerio
1 reference
Alessandra Gnani
1 reference
Sabrina Colarossi
1 reference
Marilina Amabile
1 reference
Antonella Gozzini
1 reference
Ester Orlandi
1 reference
Silvia de Matteis
1 reference
9 July 2009
1 reference
1 reference
114
1 reference
10
1 reference
2168-2171
1 reference